In this market, that was a helluva week for AVXL. Setting up nicely for next week

Price close.6.01

Anavex pipeline moving forward. Soon there will be three Phase 3 trials in progress.ANAVEX2-73 for Treatment of Early Alzheimer's Disease ON GOINGhttps://clinicaltrials.gov/ct2/show/NCT03790709ANAVEX2-73 Study in Pediatric Patients With Rett Syndrome (EXCELLENCE) ON GOINGhttps://clinicaltrials.gov/ct2/show/NCT04304482Soon there will be a Phase 3 trial for Parkinson's disease dementia and possibly Lewy body dementiahttps://www.anavex.com/anavex-life-sciences-announces-commitment-for-financial-investment-by-shake-it-up-foundation-for-parkinsons-research-for-clinical-trial-of-anavex2-73-blarcamesine-in-patients-with-par/See the Anavex pipelinehttps://www.anavex.com/wp-content/uploads/2020/10/Anavex-Pipeline-1024x509.jpgGood luck and GOD bless,

Knock, knock, $6!

Anavex Life Sciences Corp. (AVXL) Soars 6.88% on October 29, 2020https://www.equities.com/news/anavex-life-sciences-corp-avxl-soars-6-88-on-october-29Good luck and GOD bless,

Now the flippers will tear this thing down...

Biogen's failure is Avanex's gain......lets remember avxl is able to do something specific to anavex and that is pass thru the blood barrier in the brain which is a gateway to a cure for parkinsons AND alzheimers.......if successful and we are headed that way after years of research and development then the road for investors is finally going to pay off big with either a buyout or a big move up in price.....i will be happy with either ~~~~~~~~~

Experts in the industry are saying Biogen will have a very tough time finding success with Aducanumab (their Alz drug trial). Will know on Nov 6th as a committee of some of these outside experts will advise the FDA on Biogen's application to market its treatment. If they run into another hurdle or failure with Aducanumab then Biogen may need to seriously consider shelving this approach once and for all - and possibly take a much closer look at AVXL and its approach via A2-73 (as this Alz marketplace, very conservatively, is $5 - $8 Billion "annually")!!!Should know a lot more on Nov 6th!!

What a great stock! It only went down 1.32%, unlike the rest of the market. I thank Georgie girl for telling me about this Corporation. Georgie girl knows his Pharmas!

Small Molecules Selectively Targeting Sigma-1 Receptor for the Treatment of Neurological DiseasesNa Ye 1, Wangzhi Qin 1, Sheng Tian 1, Qingfeng Xu 1, Eric A Wold 2, Jia Zhou 2, Xue-Chu Zhen 1Affiliations collapseAffiliations1Jiangsu Key Laboratory of Neuropsychiatric Diseases and College of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu 215123, China.2Chemical Biology Program, Department of Pharmacology and Toxicology, and Center for Addiction Research, University of Texas Medical Branch, Galveston, Texas 77555, United States.PMID: 33111525 DOI: 10.1021/acs.jmedchem.0c01192AbstractThe sigma-1 (s1) receptor, an enigmatic protein originally classified as an opioid receptor subtype, is now understood to possess unique structural and functional features of its own and play critical roles to widely impact signaling transduction by interacting with receptors, ion channels, lipids, and kinases. The s1 receptor is implicated in modulating learning, memory, emotion, sensory systems, neuronal development, and cognition and accordingly is now an actively pursued drug target for various neurological and neuropsychiatric disorders. Evaluation of the five selective s1 receptor drug candidates (pridopidine, ANAVEX2-73, SA4503, S1RA, and T-817MA) that have entered clinical trials has shown that reaching clinical approval remains an evasive and important goal. This review provides up-to-date information on the selective targeting of s1 receptors, including their history, function, reported crystal structures, and roles in neurological diseases, as well as a useful collation of new chemical entities as s1 selective orthosteric ligands or allosteric modulators.https://pubmed.ncbi.nlm.nih.gov/33111525/Good luck and GOD bless,

Hey Paul how’s your friends tip working for you now?

Fighting to stay green in a big down day as the data will be very compelling!! Getting closer and closer to the big day!!!

7.50 by November 15th hold on AVXL is on the move.

extremely encouraging data.Quote:“As the first double-blind trial of ANAVEX®2-73 (blarcamesine) in PDD, this proof-of-concept study provides extremely encouraging data. PDD can be debilitating with significant co-morbidities. New therapies are urgently needed to alleviate this suffering and disability. There has not been a mechanistically novel medication approved for PDD in over 20 years.”https://www.globenewswire.com/news-release/2020/10/15/2109061/0/en/Anavex-Life-Sciences-Announces-Positive-Results-from-Proof-of-Concept-controlled-Phase-2-Clinical-Trial-Evaluating-ANAVEX-2-73-blarcamesine-in-Parkinson-s-Disease-Dementia.htmlGood luck and GOD bless.

Anavex Life Sciences Corp. (AVXL) 14-day ATR is 0.38: This Stock is Set to Soar Above its Peershttps://newsdaemon.com/2020/10/26/anavex-life-sciences-corp-avxl-14-day-atr-is-0-38-this-stock-is-set-to-soar-above-its-peers/Good luck and GOD bless,

My friend, John Johnson, who is a member of my Catholic Church, has been praising this Corporation and its stock for a long time. I finally bought 1,000 shares this morning at $5.45 per share. Thank you John I already made a little money.

Dr. Jaime Kulisevsky Bojarski, MD, PhD:Quote:"As the first double-blind trial of ANAVEX®2-73 (blarcamesine) in PDD, this proof-of-concept study provides extremely encouraging data. PDD can be debilitating with significant co-morbidities....:"Dr. Dag Aarsland, MD, PhD"Quote:“I am very pleased to see the promising results of the ANAVEX®2-73-PDD-001 trial, providing significant improvements in cognitive function accompanied by a favorable safety and tolerability profile...”https://www.globenewswire.com/news-release/2020/10/15/2109061/0/en/Anavex-Life-Sciences-Announces-Positive-Results-from-Proof-of-Concept-controlled-Phase-2-Clinical-Trial-Evaluating-ANAVEX-2-73-blarcamesine-in-Parkinson-s-Disease-Dementia.htmlGood luck and GOD bless,

Avxl could be the next Appel stock......the upside is so high it is in the clouds......It may have days in the future when it goes up 40 points in a day.....and it probably will............so many great things happening for this company.

Was this just a lot of trades set up at $6?

They are to full results announce on November 6 can call investors relation to verify